(Q42239677)

English

Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial

scientific article published on 28 January 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

phase III clinical trial

0 references

influenza vaccine

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

8

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

author name string

Juan Carlos Tinoco

1

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Noris Pavia-Ruz

2

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Aurelio Cruz-Valdez

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Carlos Aranza Doniz

4

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Vijayalakshmi Chandrasekaran

5

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Walthère Dewé

6

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Aixue Liu

7

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Varsha K Jain

9

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

language of work or name

0 references

publication date

28 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1480-1487

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Influenza-associated hospitalizations in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.022

7 January 2021

The rationale for quadrivalent influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.022

7 January 2021

Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a defined population over four seasons: 2004-2005 through 2007-2008.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.022

7 January 2021

Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.022

7 January 2021

Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.022

7 January 2021

Surveillance and vaccine effectiveness of an influenza epidemic predominated by vaccine-mismatched influenza B/Yamagata-lineage viruses in Taiwan, 2011-12 season

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.022

7 January 2021

Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.022

7 January 2021

Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.022

7 January 2021

Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow-fill-seal device in adults: a randomized, active-controlled study*

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.022

7 January 2021

A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.022

7 January 2021

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.022

7 January 2021

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.022

7 January 2021

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.022

7 January 2021

Identifiers

10.1016/J.VACCINE.2014.01.022

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42239677&oldid=2170949821"